2026-06-27T08:05:15Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/113252026-02-05T01:05:53Zcom_10259_11322com_10259_3591com_10259.4_106com_10259_2604col_10259_11323

00925njm 22002777a 4500 dc Martínez Alonso, Marta author Jones, Callum G. author Shipp, James D. author Chekulaev, Dimitri author Bryant, Helen E. author Weinstein, Julia A. author 2024-02 Two novel cyclometallated iridium(III) complexes have been prepared with one bidentate or two monodentate imidazole-based ligands, 1 and 2, respectively. The complexes showed intense emission with long lifetimes of the excited state. Femtosecond transient absorption experiments established the nature of the lowest excited state as 3IL state. Singlet oxygen generation with good yields (40% for 1 and 82% for 2) was established by detecting 1O2 directly, through its emission at 1270 nm. Photostability studies were also performed to assess the viability of the complexes as photosensitizers (PS) for photodynamic therapy (PDT). Complex 1 was selected as a good candidate to investigate light-activated killing of cells, whilst complex 2 was found to be toxic in the dark and unstable under light. Complex 1 demonstrated high phototoxicity indexes (PI) in the visible region, PI > 250 after irradiation at 405 nm and PI > 150 at 455 nm, in EJ bladder cancer cells. 0949-8257 https://hdl.handle.net/10259/11325 10.1007/s00775-023-02031-z 1432-1327 PDT Anticancer drugs Iridium Phototoxicity Phototoxicity of cyclometallated Ir(III) complexes bearing a thio-bis-benzimidazole ligand, and its monodentate analogue, as potential PDT photosensitisers in cancer cell killing